key: cord-0704041-rh6hq68v
authors: Amaral, Jackson L.; Oliveira, Jose T. A.; Lopes, Francisco E. S.; Freitas, Cleverson D. T.; Freire, Valder N.; Abreu, Leonardo V.; Souza, Pedro F. N.
title: Quantum biochemistry, molecular docking, and dynamics simulation revealed synthetic peptides induced conformational changes affecting the topology of the catalytic site of SARS-CoV-2 main protease
date: 2021-05-05
journal: Journal of biomolecular structure & dynamics
DOI: 10.1080/07391102.2021.1920464
sha: 8ed1a1ccfa15579b78cf010a7ace28df85830f96
doc_id: 704041
cord_uid: rh6hq68v

The recent outbreak caused by SARS-CoV-2 continues to threat and take many lives all over the world. The lack of an efficient pharmacological treatments are serious problems to be faced by scientists and medical staffs worldwide. In this work, an in silico approach based on the combination of molecular docking, dynamics simulations, and quantum biochemistry revealed that the synthetic peptides RcAlb-PepI, PepGAT, and PepKAA, strongly interact with the main protease (Mpro) a pivotal protein for SARS-CoV-2 replication. Although not binding to the proteolytic site of SARS-CoV-2 Mpro, RcAlb-PepI, PepGAT, and PepKAA interact with other protein domain and allosterically altered the protease topology. Indeed, such peptide-SARS-CoV-2 Mpro complexes provoked dramatic alterations in the three-dimensional structure of Mpro leading to area and volume shrinkage of the proteolytic site, which could affect the protease activity and thus the virus replication. Based on these findings, it is suggested that RcAlb-PepI, PepGAT, and PepKAA could interfere with SARS-CoV-2 Mpro role in vivo. Also, unlike other antiviral drugs, these peptides have no toxicity to human cells. This pioneering in silico investigation opens up opportunity for further in vivo research on these peptides, towards discovering new drugs and entirely new perspectives to treat COVID-19. Communicated by Ramaswamy H. Sarma

The current coronavirus outbreak caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the third epidemic event related to Coronaviruses in the last twenty years. The other two outbreaks that were caused by severe acute respiratory syndrome coronavirus 1 (SARS-CoV-1) and Middle East respiratory syndrome coronavirus (MERS-CoV) absolutely were not as severe and aggressive as SARS-CoV-2 (Song et al., 2019; WHO, 2020) . To date, SARS-CoV-2 has infected 20,972,577 people in 215 countries with 750,377deaths (CDC, n.d; Hui et al., 2020; Practice, 2020) and transmission still continues to accelerate in different geographic region of the world. Often, the main problem caused by SARS-CoV-2 in infected patients is the immune response triggered against the virus infection. This immune reaction is characterized by overproduction of the proinflammatory cytokines tumor necrosis factors (TNFs) and interleukins IL-6 and 1, known as the "cytokine storm," which is a hyperinflammatory state that led to multiple-organ damage and dysfunction, specially of lungs, heart, liver, and kidneys Ragab et al., 2020; Tang et al., 2020) .

First identified in Wuhan, China, genomic data analysis revealed that the human coronavirus SARS-CoV-2 has 70% genetic similarity with SARS-CoV-1 (Almaz an et al., 2014; Wu et al., 2020) . One of the common features amongst these coronaviruses is that they entry in human cells by physical interaction of the viral spike glycoprotein (S protein) with the human angiotensin-converting enzyme 2 (ACE2) receptor, which is located at the cell membrane. Subsequently, conformational alteration of the S protein permits both the viral envelope to combine with the outer membrane and the transport of the virus' genetic material inside the human cell. However, amino acid sequence data analysis showed the SARS-CoV-2 S protein possesses mutations in the receptorbinding domain (RBD), in relation to that of SARS-CoV-1 S protein. Such genetic alteration leads to 20-fold increased affinity of SARS-CoV-2 S protein to ACE2, compared to SARS-CoV-1 S protein, and enhanced infectivity and velocity of SARS-CoV-2 spreading in humans (Souza et al., 2021; Hoffmann et al., 2020; Yuan et al., 2017) . Once inside the

Blind molecular docking analyses were carried out in FRODOCK 3.12 (Ram ırez-Aportela et al., 2016) and ClusPro 2.0 (https://cluspro.org), using the synthetic peptides as ligands against SARS-CoV-2 Mpro. Docking scores were used to select the peptides with the highest potential for interaction with SARS-CoV-2 Mpro. A score of 1 was assigned to the peptide with the highest docking value (referred to as the top scored pose). The scores of the subsequent peptides were decreased successively by a factor of 0.125 as the docking values decreased in relation to that of the peptide that received score 1. The peptide score obtained in the FRODOCK was added to that generated by ClusPro. Based on the sum of scores, the three peptides with the highest potential were used to conduct the subsequent studies.

To stabilize the complexes formed between SARS-CoV-2 Mpro and the studied peptides before molecular dynamics simulation using Gromacs version 2018 .4 (Van Der Spoel et al., 2005 , they were minimized and equilibrated. OPLS-AA/L all-atom force field (Moal & Bates, 2010; Robertson et al., 2015) was used to build molecular topology. Then, a cubic water box of edge length 2 nm was created. Box solvation was done with the SPC/E water model, the systems were neutralized, and Na þ and Cl À added at 0.15 M concentration. Energy minimization of the complex structure was carried out until a negative potential energy and a maximum force below 10 3 kJ mol À1 nm À1 were attained. Next, temperature and pressure equilibration were performed during 100 ps simulation. Molecular dynamics simulations, in duplicate, were performed during 100 ns and the final structures generated were used for further analysis.

This analysis was carried out using the Protein Interactions Calculator (PIC) webserver (http://pic.mbu.iisc.ernet.in/). The 2D figures showing hydrogen bonds and hydrophobic interactions were built using the Ligplot software (Laskowski & Swindells, 2011) . The Pymol software was used to generate 3D structures and to calculate RMSD (root mean square deviation) (Laskowski et al., 2018) . CASTp 3.0 (Tian et al., 2018) was used to assess changes in the area and volume of the proteolytic site of the SARS-CoV-2 main protease (SARS-CoV-2 M'pro) when alone and complexed with the studied peptides.

This was performed according to a protocol established previously by Zhang and Zhang (2003) . Molecular fractionation with conjugate caps (MFCC) was carry out to calculate in silico the full quantum mechanical interaction energies between two pairs of specific amino acid residues (Ri and Rj) involving the studied peptides and SARS-CoV-2 Mpro, as follows, based on the work of Amaral et al. (2020) :

Where E(C i-1 R i C iþ1 þ C j-1 R j C jþ1 ), the first term of the equation, is the total energy of the system formed by the residues Ri and Rj correctly capped; E(C i-1 R i C iþ1 þ C j-1 C jþ1 ), the second term, is the total energy of the system formed by the capped residue Ri and the caps of the residue Rj; the third term, E(C i-1 C iþ1 þ C j-1 R j C jþ1 ), represents the total energy of the system formed by the capped residue Rj and the caps of the residue Ri; and the last term, E(C i-1 C iþ1 þ C j-1 C jþ1 ), accounts for the total energy of the system formed by the caps of both residues Ri and Rj. The caps C i-1 (C iþ1 ) and C j-1 (C jþ1 ) are made from the residues covalently bound to the amine (carboxyl) groups of Ri and Rj. In the MFCC method used, all interaction between amino acid residues of the studied peptides and SARS-CoV-2 Mpro separated from each other within a 8 Å range were calculated, considering a dielectric function approaches of 40 (E ¼ 40) for all interactions. The structural files (PDB format) obtained after molecular dynamics simulation and MFCC were used as inputs for density functional theory calculations with DMOL 3 (Delley, 2000) .

Before molecular dynamics and quantum biochemistry analyses, molecular docking simulations were run on the FRODOCK 3.12 and ClusPro 2.0 webservers to find out which peptides best interact with SARS-CoV-2 Mpro. Both servers calculated that the eight studied peptides bind strongly to SARS-CoV-2 Mpro with score values that varied from 1700.10 to 2182.11 (Table 1) . ClusPro 2.0 was used to calculate the free energies (DG) of interactions, which were low and varied from À579.1 to À736.5 kcal.mol À1 (Table 1 ). The sum of the punctuations provided by FRODOCK and ClusPro 2.0 was used to select RcAlb-pepII, PepGAT, and PepKAA as the best peptides, in relation to their capacity of binding to SARS-CoV-2 Mpro, with punctuation values of 1.500, 1.375, and 1.375, respectively (Table 1) . Molecular docking analysis also revealed that these peptides do not bind to the proteolytic site of SARS-CoV-2 Mpro (His 41 and Cys 145 ) ( Figure 1 ). Nevertheless, RcAlb-pepII, PepGAT, and PepKAA were further analyzed using molecular dynamics and quantum biochemistry.

Molecular dynamics simulations were done with SARS-CoV-2 Mpro alone and complexed with the peptides RcAlb-pepII, PepGAT, and PepKAA. RMSD of SARS-CoV-2 Mpro alone and complexed with the peptides increased gradually up to 1.5 Å within 50 ns and then remained stable until 100 ns, with RMSD fluctuation below 1 Å ( Figure 2 ). The stable conformation obtained from each molecular dynamics simulation was used to perform further analyzes.

The key amino acid residues responsible for the multi-point binding interactions between SARS-CoV-2 Mpro and RcAlb-PepII were Lys 137 , Asn 274 , Met 276 , Tyr 237 , and Asn 277 with Leu 9 , Lys 2 , Lys 2 , Pro 5 , and Lys 2 (Table 2; Figure 3A , B and D) with interaction energy of À12.13, À8.30, À4.82, À4.60, and À3.75 kcal.mol À1 , respectively (Table 2) . Repulsive interactions occur between the amino acid residues Asp 197 , Lys 137 , and Glu 290 of SARS-CoV-2 Mpro with Leu 9 , Ala 8 , and Leu 9 of RcAlb-PepII, with interaction energy of þ1.64, þ1.66, and þ1.92 kcal mol À1 and distance of 1.64, 1.66, and 1.92 Å, respectively (Table 2 ). Supplementary Table 1 shows the quantum parameters of the multi-point binding interactions between the amino acid residues of SARS-CoV-2 Mpro and those of RcAlb-PepII at distances up to 8 Å. The complex formed between SARS-CoV-2 Mpro and RcAlb-PepII is molded through hydrophobic interactions established by the amino acid residues Tyr 237 , Tyr 239 , Tyr 239 , Leu 271 , Leu 272 , Leu 272 , Met 276 , Leu 286 , Leu 286 , Leu 286 , Leu 287 , and Leu 287 of SARS-CoV-2 Mpro with Pro 5 , Ile 4 , Leu 9 , Ile 4 , Ile 4 , Pro 5 , Ile 4 , Ile 4 , Ile 7 , Leu 9 , Ile 4 , and Leu 9 of RcAlb-PepII ( Figure 3A , B and D). Hydrogen bonds are established between the amino acid residues Met 276 and Asn 274 of SARS-CoV-2 Mpro with Lys 2 of RcAlb-PepII ( Figure 3A , B and D). The individual interaction energy of the residues Ala 1 , Lys 2 , Leu 3 , Ile 4 , Pro 5 , Thr 6 , Ile 7 , Ala 8 , Leu 9 was À5.28, À20.44, À3.55, À10.60, À5.86, À0.74, À11.58, À5.98, and À10.83 kcal.mol À1 , respectively ( Figure 3C ). 1.000 À632.7 0.375 1.375 a Calculated using the FRODOCK v.3.12 server. b,d Punctuation is associated with both the FRODOCK score and the ClusPro lowest binding free energy (kcal mol À1 ), respectively. A score of 1 was assigned to the peptide with the highest docking value (referred to as the top scored pose). The scores of the subsequent peptides were decreased successively by a factor of 0.125 as the docking values decreased in relation to that of the peptide that received score 1. c The lowest binding free energy (DG) calculated using ClusPro 2.0. eRepresents the sum of the scores (punctuation) in b and d.

Distances (Å), total free energy of interaction (kcal mol À1 ), amino acid residue charge and amino acid residue atom closest (up to 8 Å) to the interactions between SARS-CoV-2 Mpro and PepGAT are shown in the supplementary Table 2 . Interaction between SARS-CoV-2 Mpro and PepGAT was establish predominantly by Gln 306 , Gln 306 , Asp 153 , Asp 248 , Phe 294 , Gln 110 , Ile 249 , Phe 294 , and Asp 245 with Gly 1 , Arg 5 , Gly 1 , Arg 10 , Arg 5 , Thr 3 , Arg 10 , Ala 2 , and Arg 10 , with interaction energy of À19.62, À12.35, À11.12, À10.39, À6.28, À4.73, À4.51, À3.96, and À3.89 kcal.mol À1 , and distances of 1.57, 2.32, 2.50, 2.80, 2.31, 2.23, 2.10, 4.12, and 2.54 Å, respectively, to form stable complex (Table 3 ; Figure 4A and B). Repulsive interactions occur mainly between the amino acid residues Arg 298 , Lys 102 , and Phe 305 of the protease with Gly1 of the peptide, with interaction energy of þ1.47, þ2.26, and þ2.79 kcal.mol À1 and distances of 6.14, 5.39, and 3.49 Å, respectively (Table 3) .

Supplementary Table 2 shows the quantum parameters of the multi-point binding interactions between the amino acid residues of SARS-CoV-2 Mpro and those of PepGAT at distances up to 8 Å. SARS-CoV-2 Mpro establishes hydrophobic, ionic, cation-pi and hydrogen bond interactions with PepGAT. Hydrogen bonds are established between the amino acid residues Gln 110 , Asp 153 , and Asp 248 of SARS-CoV-2 Mpro with Thr 3 , Gly 1 , and Arg 10 of PepGAT ( Figure 4A , B, and D). The ionic interactions occur between the amino acid residues Asp 245 and Asp 248 of Mpro with Arg 10 of PepGAT ( Figure 4A , B and D). A cation-pi interaction is formed by Phe 294 of SARS-CoV-2 Mpro with Arg 10 of PepGAT. Hydrophobic interactions are established by the amino acid residues Val 104 , Ile 249 , Phe 294 , and Phe 294 of SARS-CoV-2 Mpro with Ile 4 , Ala 6 , Ala 2 , and Ala 6 of PepGAT ( Figure 4B and D). The individual interaction energy of the residues Gly 1 , Ala 2 , Thr 3 , Ileu 4 , Arg 5 , Ala 6 , Val 7 , Asn 8 , Ser 9 , and Arg 10 of PepGAT was À19.73, À6.59, À12.20, À12.10, À16.45, À3.56, À6.26, À0.80, À0.74, and À22.80 kcal.mol À1 , respectively ( Figure 4C ).

The key amino acid residues responsible for the multi-point binding interactions between SARS-CoV-2 Mpro and PepKAA are Asp 245 , Asp 248 , Asp 248 , Gln 256 , Phe 294 , Asp 153 , Ile 249 , Pro 252 , and Val 297 with Arg 5 , Arg 5 , Lys 1 , Phe 9 , Tyr 8 , Lys 7 , Arg 5 , Tyr 8 , and Tyr 8 with interaction energy of À11.93, À11.32, À10.36, À6.55, À6.08, À4.93, À4.03, À3.60, and À3.29 kcal.mol À1 and distances of 1.68, 1.76, 3.71, 2.70, 2.31, 3.79, 2.60, 2.14, and 2.14 Å, respectively (Table 4 ). The repulsive interactions occur between Val 247 and Lys 102 of SARS-CoV-2 Mpro with Arg 5 and Lys 7 of PepKAA, with interaction energy of þ0.58 and þ1.34 kcal.mol À1 and distances of 6.08 and 7.05 Å, respectively (Table 4 ). Supplementary Table 3 shows the quantum parameters of the multi-point binding interactions between the amino acid residues of SARS-CoV-2 Mpro and those of PepKAA at distances up to 8 Å. SARS-CoV-2 Mpro binds to PepKAA through hydrophobic, ionic, aromatic, and hydrogen bond interactions. Figure 5A and D) . The individual interaction energy of the residues Lys 1 , Ala 2 , Ala 3 , Asn 4 , Arg 5 , Ile 6 , Lys 7 , Tyr 8 , Phe 9 , Gln 10 of PepKAA was À6.27, À1.06, þ0.05, À0.80, À25.54, À2.34, À11.91, À22.90, À13.16, and À8.42 kcal.mol À1 , respectively ( Figure 5C ). 

The most important amino acid residues of SARS-CoV-2 Mpro that interact with RcAlb-PepII are Leu 287 , Leu 286 , Asn 274 , Gly 275 , Met 276 , Lys 137 , Tyr 237 , Leu 272 , and Asn 277 with interaction energy of À9.36, À9.03, À8.78, À6.47, À6.46, À6.41, À5.97, À5.80, and À5.60 kcal.mol À1 , respectively. The Asp 197 , Asp 289 , and Glu 290 residues showed repulsive energies ( Figure 6A ). The sum of all free energies of interaction between SARS-CoV-2 Mpro and RcAlb-PepII (Et) was -74.85 kcal.mol À1 (Figure 7) .

The key amino acid residues involved in the interaction of SARS-CoV-2 Mpro with the PepGAT are Asp 153 , Gln 306 , Phe 294 , Asp 248 , and Asp 245 with interaction energy of À12.47, À11.27, À8.36, À6.67, and À4.72 kcal.mol À1 , respectively. Residues of Arg 298 , Phe 305 , Lys 102 showed small repulsive energies ( Figure 6B ). The sum of all free energies of interaction between SARS-CoV-2 Mpro with PepGAT was -101.2 kcal.mol À1 (Figure 7) .

The major amino acid residues of the interaction between SARS-CoV-2 Mpro and PepKAA are Asp 248 , Pro 252 , Phe 294 , Asp 153 , and Asp 245 , with interaction energy of À20.14, À11.27, À10.15, À9.57, and À8.17 kcal. mol À1 , respectively. Lys 102 showed a small repulsive energy ( Figure 6C ). The sum of all free energies of interaction between SARS-CoV-2 Mpro and PepKAA was -92.35 kcal.mol À1 (Figure 7) .

by RcAlb-PepII, PepGAT, and PepKAA in the area and volume of the proteolytic site of SARS-CoV-2 Mpro RMSD analyses revealed that RcAlb-PepII, PepGAT, and PepKAA induced alterations in the 3D structure of SARS-CoV-2 Mpro (Figure 8 ). The control structure presented RMSD value of 0, which indicates a typical and functional 3D structure ( Figure 8A ). However, the structural alignment of SARS-CoV-2 Mpro complexed with RcAlb-PepI, PepGAT, or PepKAA revealed several alterations in the SARS-CoV-2 Mpro structure, which was confirmed by the RMSD values of 3.118, 3.164, 3.054 Å, respectively ( Figure 8B -D). These structural changes in SARS-CoV-2 Mpro induced by interactions with the studied peptides lead to alterations in the area and volume of the SARS-CoV-2 Mpro proteolytic site. SARS-CoV-2 Mpro itself, not complexed with the studied peptides, presented an area and volume of 279.7 Å 2 and 298.1 Å 3 , respectively ( Figure 9A ).

When complexed with RcAlb-PepII, the area and volume of SARS-CoV-2 Mpro proteolytic site reduced to 120.6 Å 2 and 93.3 Å 3 , which represent 68.7% and 56.9% decrease, respectively ( Figure 9B ). The structural changes caused by PepGAT also reflected in the area and volume of the SARS-CoV-2 Mpro proteolytic site, which decreased from 298.1 Å 2 and 279.7 Å 3 to 183.7 Å 2 and 179.0 Å 3 , resulting in a 38.4% and 36.0% decrease, respectively ( Figure 9C ). Regarding to PepKAA, its interaction with the protease promoted a 13.0% (279.7 Å 2 to 243.3 Å 2 ) and 23.1% (298.1 Å 3 to 229.2 Å 3 ) decrease, respectively, in the area and volume of the SARS-CoV-2 Mpro proteolytic site ( Figure 9D ).

Currently, there are two main ways to find out and develop medicines against SARS-CoV-2. The first one is through drug repositioning in which the antiviral activity of several pharmacological classes of medicines already approved for use in humans is investigated as a possibility for generating new treatments against COVID-19 (Diamond & Pierson, 2020; Serafin et al., 2020; Tay et al., 2020; . To date, such attempts have been tried unsuccessfully. The second approach is still a promise, but it is based on systematic investigations conducted to identify novel small molecules designed to target key SARS-CoV-2 factors such as the Spike glycoprotein and RNA polymerase . Such an approach involves the in silico molecular docking and molecular dynamics simulation, which are structurebased method employed to predict the binding affinity of a Table 2 . Quantum parameters of the multi-point binding interactions between the amino acid residues of SARS-CoV-2 Mpro and those of RcAlb-PepII. ligand molecule to a target Hall & Ji, 2020; Ngo et al., 2020; Ortega et al., 2020; . So, molecular docking and molecular dynamics simulation constitute useful tools to facilitate the drug development process as they allow to predict in silico the binding affinity of a designed ligand molecule to a target as SARS-CoV-2 Mpro . Mpro has three-domain (domains I to III) cysteine protease essential for coronavirus replication as it plays a crucial role in the processing of the viral polyproteins into mature proteins (Ziebuhr et al., 2000) . SARS-CoV-2 Mpro and SARS-CoV-1 Mpro primary structures differ by only 12 amino acid residues, which means they have 96% similarity (Estrada, 2020) . However, a considerable difference between the catalytic site of SARS-CoV-1 and that of SARS-CoV-2 is observed. In SARS-CoV-1 Mpro, the active site cavity is a well-defined pocket with the area and volume of 256.8 Å 2 and 191.24 Å 3 , respectively, compared to 352.1 Å 2 and 323.73 Å 3 of that of SARS-CoV-2 Mpro (Ortega et al., 2020) . These differences increase by 15% the proteolytic effectiveness of SARS-CoV-2 Mpro compared to that of SARS-CoV-1 Mpro (Estrada, 2020; Ortega et al., 2020; . Such higher catalytic efficiency of SARS-CoV-2 Mpro could enhance the virus replication process and formation of new virus particles, which could lead to higher infectivity. Therefore, due to its crucial involvement in maturation of most of the nonstructural proteins that are translated from SARS-CoV-2 RNA, SARS-CoV-2 Mpro is an attractive target to design antiviral drugs (Sharma et al., 2020) . Many studies have tried to either analyze new drugs or already known drugs that could interact with the catalytic site of SARS-CoV-2 Mpro and inhibit its activity (Hall & Ji, 2020; Ngo et al., 2020; Ortega et al., 2020; Sharma et al., 2020; . Moreover, drugs that have been employed to treat HIV by inhibiting the viral protease were also tested (Hall & Ji, 2020) . In this current in silico study we used molecular docking and dynamics simulations to predict and show that the synthetic peptides RcAlb-PepII, PepGAT, and PepKAA, out of eight peptides tested, interact most efficiently with SARS-CoV-2 Mpro (Table 1, Figures 1-7) . These peptides interact with SARS-CoV-2 Mpro at a region far away from the protease catalytic site, which suggests that the peptides may modulate the SARS-CoV-2 Mpro activity allosterically (Figures 8 and 9 ). Actually, this is a pioneer study in which quantum biochemistry is employed to analyze the interaction of peptides against SARS-CoV-2 Mpro (Tables  2-4 ). Quantum biochemistry calculations Sousa et al., 2016) allowed to deduce the individual energies of interactions of each amino acid residue of the studied peptides and those of SARS-CoV-2 Mpro. Therefore, it was possible to predict the hydrogen bonds, ionic, aromatic, and hydrophobic interactions that are important to establish attractive or repulsive interactions between the peptides and SARS-CoV-2 Mpro (Figures 3-6 ). Figure 7 shows that, by using quantum biochemistry calculations, the total interaction energy between RcAlb-PepII, PepGAT, and PepKAA with SARS-CoV-2 Mpro was À74.85, À101.2, and À92.35 kcal.mol À1 , respectively. As this is the first work that analyzes, through quantum biochemistry, interactions of peptides with SARS-CoV-2 Mpro, the results presented herein are compared with those reported by Campos et al. (2020) , in which the interaction of two peptides against the Zika virus protease was analyzed. The authors demonstrated, by quantum biochemistry, that the interaction energies of the peptides cn-716 and acyl-KR-aldehyde with the protease NS2B-NS3 were À63.35 kcal.mol À1 and À71.4 kcal.mol À1 , respectively. For instance, RcAlb-PepII, PepGAT, and PepKAA interacts with SARS-CoV-2 Mpro even more strongly than cn-716 and acyl-KR-aldehyde to the protease NS2B-NS3. Nevertheless, interaction of other non-peptide-like antiviral drugs have been tested with the same purpose of inhibiting the proteolytic activity of SARS-CoV-2 Mpro. For example, Ortega et al. (2020) tested by molecular docking the interaction of the clinically proven anti-HIV drugs Saquinavir, Lopinavir, and Tripranavir, which act as inhibitors of the HIV protease, with the proteolytic site of SARS-CoV-2 Mpro. Additionally, Hall and Ji (2020) reported that Remdesivir, a nucleotide analogue initially developed to treat hepatitis C and later Ebola and Marburg virus, also binds to the proteolytic site of SARS-CoV-2 Mpro. These two later studies are referred as drug reposition or drug repurposing, which is an approach to speed up the drug discovery process through identification of a novel clinical use for an existing drug approved for a different indication (Serafin et al., 2020) . Moreover, Ngo et al. (2020) docked some natural compounds and found that cannabisin A and isoacteoside interacted with the proteolytic site of SARS-CoV-2 Mpro. Currently, the most reliable inhibitor of SARS-CoV-2 Mpro, as seen by molecular docking and proven in vitro, is 13b, an A-ketoamide that is a protease inhibitor of coronavirus that strongly binds to the proteolytic site of SARS-CoV-2 Mpro . RcAlb-PepII, PepGAT, and PepKAA interact with SARS-CoV-2 Mpro at a region far away from the protease active site (Figures 1, 8, and 9 ), contrary to these above-mentioned antiviral drugs tested. However, Bz owka et al. (2020) showed that the proteolytic site of SARS-CoV-2 Mpro has high flexibility and plasticity, which means it is highly susceptible to genetic mutational change. Such possibility constitutes a serious problem for designing drugs targeting the proteolytic site because a simple genetic mutation could prevent the action of these antiviral drugs. Actually, SARS-CoV-2 Table 3 . Quantum parameters of the multi-point binding interactions between the amino acid residues of SARS-CoV-2 Mpro and those of PepGAT. is an RNA virus and has high mutational rates (Bz owka et al., 2020) and, for example, the antiviral 13 b, which strongly binds to the proteolytic site of SARS-CoV-2 Mpro , could quickly become ineffective against coronavirus. Prediction that RcAlb-PepII, PepGAT, and PepKAA interact with SARS-CoV-2 Mpro at a region far away from the protease active site (Figures 1, 8 and 9 ) is an advantage because besides their interactions being unaffected by mutation of the active site of SARS-CoV-2 Mpro, they induce conformational alterations in the 3D structure of this protease (Figure 8) , as shown by the RMSD values of SARS-CoV-2 Mpro complexed with the peptides, compared to SARS-CoV-2 Mpro alone, that could disrupt the proteolytic activity of the viral enzyme, leading to a severe reduction in SARS-CoV-2 replication. Indeed, interaction of RcAlb-PepII, PepGAT, and PepKAA reduce the volume and area of SARS-CoV-2 Mpro proteolytic site, respectively, in 56.9% and 68.7% ( Figure 9B ), 38.4% and 36.0% ( Figure 9C ), and 23.1 and 13.0% ( Figure 9D ). In a recent report by our research group, it was shown that PepKAA also induced conformational changes in the SARS-CoV-2 Spike glycoprotein, disrupting its interaction with the ACE2 receptor located at the human cell membrane . As PepKAA shows to interact with two different targets (SARS-CoV-2 Spike glycoprotein and SARS-CoV-2 Mpro of SARS-CoV-2, this particular synthetic peptide is a potential small molecule candidate to be further tested in vitro against SARS-CoV-2, either alone or combined with other peptides like RcAlb-PepII, PepGAT. Of utmost importance is that RcAlb-PepII, PepGAT, and PepKAA were not toxic to mammalian cells like rabbit erythrocytes and human ABO type red blood cells Oliveira et al., 2019; , neither to fibroblast (lines L929 and MRC-5) and keratinocytes (Data not shown, manuscript in preparation).

Quantum biochemistry and molecular dynamics simulations allow to predicted that the peptides RcAlb-PepII, PepGAT, and PepKAA interact physically with SARS-CoV-2 Mpro and alter its 3D structure and provoke shrinkage of the active site of the protease. These findings suggest that these peptides Figure 5 . The 3D and 2D structure representations of the complex formed by docking of PepKAA (Lys 1 -Ala-Ala-Asn-Arg-Ile-Lys-Tyr-Phe-Gln 10 ) on SARS-CoV-2 Mpro are depicted in A and B, respectively. The interaction energies of the amino acid residues of PepKAA with those of SARS-CoV-2 Mpro, and the amino acid residues that participate in the formation of hydrogen bond, hydrophobic, ionic, and aromatic interactions between PepKAA and SARS-CoV-2 Mpro are shown in D.

are likely antiviral small molecules that could potentially inhibit SARS-CoV-2 replication in vivo, a hypothesis that requires further investigation in the near future to be proven true. Importantly, besides to be apparently harmless to mammalian cells, RcAlb-PepII, PepGAT, and PepKAA do not interact with the active site of SARS-CoV-2 Mpro, unlike most antiviral drugs, and, thus, mutation of this protease domain will not affect the peptide effectiveness. In conclusion, this pioneering in silico investigation opens up opportunity for further in vivo investigations on these peptides, towards discovering new drugs and entirely new perspectives to treat COVID-19. For instance, peptide-based therapeutics have various advantages in relation to traditional small-molecule drugs, since peptides have higher specificity to selected targets, low toxicity because the possibility for accumulation in the body is improbable, and their synthesis is not a complex, costly, and time-consuming technique (VanPatten et al., 2020). 

No potential conflict of interest was reported by the authors.

This work was supported by grants from the following Brazilian agencies: The National Council for Scientific and Technological Development 

codes 431511/ 2016-0 and 306202/2017-4) to J.T.A.O.; the Council for Advanced Professional Training (CAPES) sponsored PFNS with a Postdoctoral Fellowships

Data curation

Funding acquisition

Writing-review and editing

Coronavirus reverse genetic systems: Infectious clones and replicons

Quantum biochemistry in cancer immunotherapy: New insights about CTLA-4/ipilimumab and design of ipilimumab-derived peptides with high potential in cancer treatment

Structural and evolutionary analysis indicate that the SARS-CoV-2 Mpro is a challenging target for small-molecule inhibitor design

Intermolecular interactions of cn-716 and acyl-KR-aldehyde dipeptide inhibitors against Zika virus

COVIDView: A weekly surveillance summary of U.S. COVID-19 activity

Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease

From molecules to solids with the DMol3 approach

The challenges of vaccine development against a new virus during a pandemic

RcAlb-PepII, a synthetic small peptide bioinspired in the 2S albumin from the seed cake of Ricinus communis, is a potent antimicrobial agent against Klebsiella pneumoniae and Candida parapsilosis

Topological analysis of SARS CoV-2 main protease

A search for medications to treat COVID-19 via in silico molecular docking models of the SARS-CoV-2 spike glycoprotein and 3CL protease

SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor

The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health -The latest 2019 novel coronavirus outbreak in Wuhan

LigPlotþ: Multiple ligand-protein interaction diagrams for drug discovery

PDBsum: Structural summaries of PDB entries

SARS-CoV-2 and viral sepsis: Observations and hypotheses

Potential covalent drugs targeting the main protease of the SARS-CoV-2 coronavirus

SwarmDock and the use of normal modes in protein-protein Docking

The urokinase plasminogen activator binding to its receptor: A quantum biochemistry description within an in/ homogeneous dielectric function framework with application to uPA-uPAR peptide inhibitors

Computational determination of potential inhibitors of SARS-CoV-2 main protease

Mo-CBP3-PepI, Mo-CBP3-PepII, and Mo-CBP3-PepIII are synthetic antimicrobial peptides active against human pathogens by stimulating ROS generation and increasing plasma membrane permeability

Unrevealing sequence and structural features of novel coronavirus using in silico approaches: The main protease as molecular target

Coronavirus disease 2019. World Health Organization

The COVID-19 cytokine storm; what we know so far

Structural bioinformatics FRODOCK 2.0: Fast protein-protein docking server

Improved peptide and protein torsional energetics with the OPLS-AA force field

Drug targets for COVID-19 therapeutics: Ongoing global efforts

Drug repositioning is an alternative for the treatment of coronavirus COVID-19

Identification of potential drug candidates to combat COVID-19: A structural study using the main protease (mpro) of SARS-CoV-2

From SARS to MERS, thrusting coronaviruses into the spotlight

Explaining RANKL inhibition by OPG through quantum biochemistry computations and insights into peptide-design for the treatment of osteoporosis

A molecular docking study revealed that synthetic peptides induced conformational changes in the structure of SARS-CoV-2 spike glycoprotein, disrupting the interaction with human ACE2 receptor

Synthetic antimicrobial peptides: From choice of the best sequences to action mechanisms

The Human Pandemic Coronaviruses on the Show: The Spike Glycoprotein as the Main Actor in the Coronaviruses Play

Cytokine storm in COVID-19: The current evidence and treatment strategies

The trinity of COVID-19: Immunity, inflammation and intervention

CASTp 3.0: Computed atlas of surface topography of proteins

GROMACS: Fast, flexible, and free

Evidence supporting the use of peptides and peptidomimetics as potential SARS-CoV-2 (COVID-19) therapeutics

Middle East respiratory syndrome coronavirus

Genome composition and divergence of the novel coronavirus (2019-nCoV) originating in China

Cryo-EM structures of MERS-CoV and SARS-CoV spike glycoproteins reveal the dynamic receptor binding domains

Molecular fractionation with conjugate caps for full quantum mechanical calculation of protein-molecule interaction energy

Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved a-ketoamide inhibitors

Protective humoral immunity in SARS-CoV-2 infected pediatric patients

Virus-encoded proteinases and proteolytic processing in the Nidovirales

The authors are also grateful to the support received from the National Center for High Performance Processing -Federal University of Ceara and Center for Permanent Education in Health Care-CEATS/School of Public Health of Ceara (ESP-CE). V.N.F. also acknowledges support from PRONEX FUNCAP/CNPq (PR2-0101-00006.01.00/15).